研究者詳細 - 香川　俊輔

論文 - 香川　俊輔

分割表示 420 件中 241 - 260 件目／全件表示 >>

がん選択的生物製剤を用いた早期大腸癌の低侵襲治療の開発

菊地覚次, 岸本浩行, 田澤大, 西崎正彦, 香川俊輔, 浦田泰生, Hoffman Robert M., 藤原俊義

日本癌治療学会誌 48 ( 3 ) 1918 - 1918 2013年9月

Selectively Replicating Oncolytic Adenoviruses Combined with Chemotherapy, Radiotherapy, or Molecular Targeted Therapy for Treatment of Human Cancers 査読

Shinji Kuroda, Shunsuke Kagawa, Toshiyoshi Fujiwara

Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition 171 - 183 2013年8月

記述言語：英語掲載種別：論文集(書籍)内論文出版者・発行元：Elsevier Inc.

Oncolytic adenovirotherapy presents a novel approach for cancer therapy. Oncolytic adenoviruses are modified to replicate and induce oncolytic cell death in cancer cells but not in normal somatic cells. The first oncolytic adenovirus to be developed was ONYX-015, an E1B-55. kDa gene-deleted oncolytic adenovirus
after which many inventive oncolytic adenoviruses have followed. H101, an oncolytic adenovirus with very similar gene constructs as ONYX-015, was approved in China as the world's first adenovirus cancer treatment in humans in 2005. Many clinical trials have revealed that oncolytic adenoviruses produce synergistic antitumor effects in combination with conventional chemotherapeutic agents, radiation, and some molecular targeted agents, although monotherapy with oncolytic adenoviruses shows limited effects. In this chapter, we discuss the developments of oncolytic adenoviruses, focusing on their synergistic effects when combined with other treatment modalities. Then we discuss the problems that must be overcome for adenoviruses to become more attractive as cancer treatment agents and to expand their clinical applications. © 2014 Elsevier Inc. All rights reserved.

DOI： 10.1016/B978-0-12-394295-1.00012-3

Scopus

researchmap

LADG、D2における神経解剖を軸とした膵上縁リンパ節郭清

黒田新士, 西崎正彦, 渡邊めぐみ, 石田道拡, 岸本浩行, 宇野太, 香川俊輔, 藤原俊義

日本消化器外科学会総会 68回 RV - 2 2013年7月

腹腔鏡補助下噴門側胃切除術における郭清手技と「観音開き法」食道残胃吻合

西崎正彦, 黒田新士, 野間和広, 渡邉めぐみ, 岸本浩行, 香川俊輔, 白川靖博, 藤原俊義

日本消化器外科学会総会 68回 O - 6 2013年7月

HER2陽性胃癌の臨床病理学的特徴と当院におけるtrastuzumabの使用経験

渡辺めぐみ, 香川俊輔, 石田道拡, 黒田新士, 岸本浩行, 宇野太, 西崎正彦, 藤原俊義

日本消化器外科学会総会 68回 RS - 2 2013年7月

テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌の低侵襲治療の開発

菊地覚次, 岸本浩行, 田澤大, 橋本悠里, 宇野太, 西崎正彦, 香川俊輔, 浦田泰生, ロバート・ホフマン, 藤原俊義

日本消化器外科学会総会 68回 RS - 2 2013年7月

A novel synergistic effect of iron depletion on antiangiogenic cancer therapy．

Ohara T, Noma K, Urano S, Watanabe S, Nishitani S, Tomono Y, Kimura F, Kagawa S, Shirakawa Y, Fujiwara T

Int J Cancer 132 ( 11 ) 2705 - 2713 2013年6月

Roux stasis syndromeの長期保存的加療に経胃瘻的空腸カテーテルを用いた1例

大岩雅彦, 香川俊輔, 重安邦俊, 金谷信彦, 宇野太, 岸本浩行, 西崎正彦, 藤原俊義

Gastroenterological Endoscopy 55 ( 5 ) 1650 - 1654 2013年5月

記述言語：日本語出版者・発行元：(一社)日本消化器内視鏡学会

74歳男性。胃癌に対する幽門側胃切除、Roux-en-Y再建術後、胃空腸吻合部通過障害を生じた。再吻合を施行したが、通過障害は遷延し、Roux stasis syndrome(RSS)と診断した。胃減圧と長期栄養管理のため、経皮内視鏡的胃瘻造設術、percutaneous endoscopic gastrostomy(PEG)を施行し、経胃瘻的に空腸カテーテル(PEG-J)を留置した。134日後に食事摂取可能になりカテーテルを抜去した。PEG-Jにより中心静脈カテーテルや経鼻胃管の長期留置を回避できることからRSSに対する長期保存治療の1選択肢になりうると考えられた。(著者抄録)

DOI： 10.11280/gee.55.1650

researchmap

Application of percutaneous endoscopic gastrostomy with jejunal extension in a case of post-gastrectomy Roux Stasis syndrome

Masahiko Oiwa, Shunsuke Kagawa, Kunitoshi Shigeyasu, Nobuhiko Kanaya, Futoshi Uno, Hiroyuki Kishimoto, Masahiko Nishizaki, Toshiyoshi Fujiwara

Gastroenterological Endoscopy 55 ( 5 ) 1650 - 1654 2013年5月

記述言語：日本語掲載種別：研究論文（学術雑誌）

We present herein on a 74-years-old man, who underwent distal gastrectomy and Roux-en-Y reconstruction for stomach cancer, and developed gastro-jejunostomy obstruction. Re-anastomosis, however, did not relieve the symptoms. Delayed gastric emptying without mechanical obstruction lead to a diagnosis of Roux stasis syndrome (RSS). To achieve both gastric decompression and nutritional therapy, a percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) was performed in two steps. Firstly, a gastrostomy was placed endoscopically and then a jejunal catheter was inserted through the gastrostomy tube. This system can feed nutritional solution through the jejunal catheter while gastric juice is drained from the gastrostomy tube. The patient was spared an uncomfortable nasal gastric tube and long-term central-venous hyperalimentation, and his RSS was completely cleared 134 days later. This experience suggested that PEG-J can be one of the options in the conservative treatment of RSS.

Scopus

researchmap

Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination

Kunitoshi Shigeyasu, Shunsuke Kagawa, Futoshi Uno, Masahiko Nishizaki, Hiroyuki Kishimoto, Akira Gochi, Toshikazu Kimura, Takaomi Takahata, Yasuyuki Nonaka, Motoki Ninomiya, Toshiyoshi Fujiwara

Cancer Chemotherapy and Pharmacology 71 ( 4 ) 937 - 943 2013年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

Purpose: Peritoneal dissemination is the most frequent and life-threatening mode of metastasis and recurrence in patients with gastric cancer. A multicenter phase II study was designed to evaluate the efficacy and tolerability of S-1 and docetaxel combination chemotherapy regimen for the treatment of advanced or recurrent gastric cancer patients with peritoneal dissemination. Methods: Nineteen patients with histologically confirmed unresectable or recurrent gastric cancer with peritoneal dissemination were enrolled. Oral S-1 at 80 mg/m2/day was administered twice daily for 2 weeks, followed by 1 drug-free week. Docetaxel infusion at 40 mg/m2 was performed on day 1, simultaneous with S-1 administration. The primary endpoints were overall survival (OS) and time to progression (TTP). The secondary endpoints were the response rates and safety status. Results: Patients received a median of 4 cycles of the S-1 and docetaxel regimen (range 1-43). The disease control rate was 73.7 % (14/19). Median overall survival was 459 days (15.3 months), while median time to progression was 212 days (7.1 months). Neutropenia was the most common type of toxicity (n = 7, 36.8 %). Conclusions: Combination chemotherapy with S-1 and docetaxel is a tolerable and effective treatment for advanced or recurrent gastric cancer patients with peritoneal dissemination. © 2013 Springer-Verlag Berlin Heidelberg.

DOI： 10.1007/s00280-013-2086-0

Scopus

PubMed

researchmap

癌微小リンパ節転移を標的とするテロメラーゼ特異的制限増殖型ウイルス製剤の開発

児島亨, 渡邉雄一, 橋本悠里, 黒田新士, 山崎泰源, 矢野修也, 田澤大, 宇野太, 香川俊輔, 田中紀章, 浦田泰生, 藤原俊義

岡山医学会雑誌 125 ( 1 ) 9 - 12 2013年4月